Compare FRAF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | IFRX |
|---|---|---|
| Founded | 1906 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2M | 303.4M |
| IPO Year | 1995 | 2017 |
| Metric | FRAF | IFRX |
|---|---|---|
| Price | $62.76 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 32.0K | ★ 972.4K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $42.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.52 | $0.74 |
| 52 Week High | $64.88 | $2.95 |
| Indicator | FRAF | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 36.69 |
| Support Level | $54.80 | $1.54 |
| Resistance Level | $64.00 | $1.71 |
| Average True Range (ATR) | 2.11 | 0.12 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 54.94 | 10.75 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.